

S. K. BANSAL & CO.

CHARTERED ACCOUNTANTS

Kothi No. : 3193, Sector 28-D,

Changigarh-160 002

E-mail : skbansalandco@gmail.com

Website : www.bansals.in

Phones : Off. : 2657202

2651578

2657644

Fax : 2652428

Limited Review Report to the Board of Directors

We have reviewed the accompanying statement of unaudited financial results as enclosed of **M/s Parabolic Drugs Limited having Registered Office at SCO 99-100, Top Floor, Sector-17B, Chandigarh for the Quarter/three months ended 30th June 2014** except for the disclosures regarding 'Public Shareholding' and 'Promoter and Promoter Group Shareholding' which have been traced from disclosures made by the management and have not been audited by us. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.


We conducted our review in accordance with the Standard on Review Engagement (SRE) 2400, engagements to Review Financial Statements issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above subject to Annexure-A, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Clause 41 of the Listing Agreement including the manner in which it is to be disclosed, or that it contains any material misstatement.

Chandigarh;

Dated: 14th August 2014

**FOR S.K. BANSAL & CO.,
CHARTERED ACCOUNTANTS
FRN No.002222N**



(Signature)
(S.K.Bansal)
Membership No: 013147

Annexure A

Notes on the Un audited financial results of M/s Parabolic Drugs Limited

For the Quarter/Three months ended 30th June 2014

1. Debit or Credit Balances on whatever account are subject to confirmation.
2. Depreciation has been provided for on pro-rata basis as per Companies Act, 1956.
3. The Net Sales of Rs.109.64 crores for the three months ended 30th June 2014 includes trading sale of Rs.56.08 crores.
4. Figures of the previous year/Quarter/Three months have been rearranged/regrouped wherever considered necessary.

Chandigarh;
Dated: 14th August 2014

FOR S.K. BANSAL & CO.,
CHARTERED ACCOUNTANTS
FRN No.002222N



(Signature)
(S.K.Bansal)
Membership No: 013147



Parabolic Drugs Limited

Registered Office: SCO. 99 - 100, Top Floor, Sector - 17B, Chandigarh
Statement of un - audited Financial Results for the Quarter ended 30th June, 2014

(Rs. Crores)

Particulars	Three months ended 30/06/2014	Preceding Three months ended 31/03/2014	Corresponding Three months Ended 30.06.2013 in Prev. Year	Year to date figures for Current Year ended 31/03/2014
	Unaudited	Audited Stand-alone	Unaudited Stand-alone	Audited Stand-alone
Income from Operations				
Gross Sales	113.63	116.18	97.82	446.71
Less : Excise Duty	(3.99)	(4.13)	(1.47)	(16.33)
(a) Net Sales/Income from Operations (Net of excise duty)	109.64	112.05	96.35	430.38
(b) Other Operating Income	0.84	7.51	3.13	20.20
Total Income from Operations (net)	110.48	119.56	99.48	450.58
Expenses				
(a) Cost of Materials Consumed	95.67	94.22	92.62	390.62
(b) Changes in Inventories of finished goods, work-in-progress and stock-in-trade	-	(0.67)	(7.96)	(21.40)
(c) Employee Benefits Expense	4.67	4.53	3.91	18.55
(d) Depreciation & Amortisation Expense	17.23	17.02	17.04	68.08
(e) Other Expenses (Any item exceeding 10% of the total expenses relating to continuing operations to be shown separately)	8.81	98.57	8.52	131.68
Total Expenses	126.38	213.67	114.13	587.53
Profit/(Loss) from Operations before Other Income, Finance Costs & Exceptional Items (1 - 2)	(15.90)	(94.11)	(14.65)	(136.95)
Other Income				
Profit/(Loss) from ordinary activities before finance costs and exceptional items (3 + 4)	(15.90)	(94.11)	(14.65)	(136.95)
Finance Costs	18.14	23.55	20.00	83.07
Profit/(Loss) from ordinary activities after finance costs but before exceptional items (5-6)	(34.04)	(117.66)	(34.65)	(220.02)
Exceptional Items				
Profit/(Loss) from Ordinary Activities before tax (7 + 8)	(34.04)	(117.66)	(34.65)	(220.02)
Tax expense	(10.52)	(29.67)	(10.70)	(61.30)
Net Profit/(Loss) from Ordinary Activities after tax (9 - 10)	(23.52)	(87.99)	(23.95)	(158.72)
Extra Ordinary Items (net of tax expense)		(26.98)	-	(26.98)
Net Profit / (Loss) for the period (11-12)	(23.52)	(61.01)	(23.95)	(131.74)
Share of Profit/(Loss) of Associates				
Minority Interest				
Net Profit/(Loss) after taxes, minority interest and share of profit/(loss) of Associates (13 + 14 + 15)	(23.52)	(61.01)	(23.95)	(131.74)
Paid-up equity share capital (Face Value of the Share shall be indicated) (Rs. 10/- each)	61.89	61.89	61.89	61.89
Reserve excluding Revaluation Reserves as per balance sheet of previous accounting year				226.76
Earnings Per Share (EPS) (before extraordinary items) -Shares of Rs. 10/- each (not annualised)				
(a) Basic	(3.80)	(9.86)	(3.87)	(21.29)
(b) Diluted	(3.80)	(9.86)	(3.87)	(21.29)
Earnings Per Share (EPS) (after extraordinary items) -Shares of Rs. 10/- each (not annualised)				

Parabolic Drugs Limited
 Chandigarh

Parabolic Drugs Limited
 Chandigarh

	(3.80)	(9.86)	(3.87)	(21.29)
ated	(3.80)	(9.86)	(3.87)	(21.29)
PARTICULARS OF SHAREHOLDING				
Public Shareholding :				
- Number of Shares	37987970	38182935	38424587	38182935
- Percentage of Shareholding	61.38	61.69	62.08	61.69
Promoters and Promoter Group Shareholding :				
(a) Pledged/Encumbered				
- Number of shares	22556590	22372320	22162807	22372320
- Percentage of shares (as a % of the total shareholding of promoter and promoter group)	94.36	94.36	94.44	94.36
- Percentage of shares (as a % of the total share capital of the company)	36.45	36.14	35.81	36.14
(b) Non-Encumbered				
- Number of shares	1347454	1336759	1304620	1336759
- Percentage of shares (as a % of the total shareholding of promoter and promoter group)	5.64	5.64	5.56	5.64
- Percentage of shares (as a % of the total share capital of the company)	2.18	2.16	2.11	2.16

INVESTOR COMPLAINTS	Quarter ended 30/06/2014
Pending at the beginning of the quarter	Nil
Received during the quarter	2
Disposed of during the quarter	2
Remaining unresolved at the end of the quarter	Nil
TOTAL	Nil

Notes :

1. The above quarterly results have been reviewed by the Audit Committee and taken on record by the Board of Directors in their meeting held on 14th AUG 2014 and the same have been audited by the Statutory Auditors, as required under Clause 41 of the Listing Agreement.
2. During the period under review, the company has incurred loss. Owing to the tightened market conditions and economic stress, the company has witnessed an erosion in the margins of key products.
3. There is not more than one reportable segment, hence, information as per AS-17 is not required to be disclosed.
4. The Company's CDR Package stands implemented with effect cut off date being 30th September, 2012.
5. Figures of the previous year / period have been rearranged/regrouped wherever considered necessary.
6. Promoters shareholding (22556590 shares) has been pledged pursuant to the terms of CDR package.

Place : Chandigarh
Date : 14th Aug, 2014

For Parabolic Drugs Ltd.
3rd, 4th Floor
Sect. 17B
Pranav Gupta
Managing Director

